Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 2/20 | 0.58 |
| ▸ | USP30 | Q70CQ3 | 9/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.49 |
| ▸ | OTUD7B | Q6GQQ9 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14408007 | 0.82 | CNR2 (0.59) | UCHL1USP30CNR2MKNK1NPY5R | |
| SCHEMBL14408008 | 0.82 | CNR2 (0.59) | UCHL1USP30CNR2MKNK1NPY5R | |
| SCHEMBL22494614 | 0.79 | UCHL1 (0.63) | UCHL1USP30CNR2MKNK1OTUD7B | |
| SCHEMBL14407987 | 0.79 | CNR2 (0.64) | UCHL1USP30CNR2MKNK1NPY5R | |
| SCHEMBL22494615 | 0.79 | UCHL1 (0.63) | UCHL1USP30CNR2MKNK1OTUD7B | |
| SCHEMBL22494673 | 0.79 | UCHL1 (0.63) | UCHL1USP30CNR2MKNK1OTUD7B | |
| SCHEMBL20877547 | 0.79 | CCNE1 (0.45) | USP30CNR2CCNE1CDK2CDK5 | |
| SCHEMBL20883085 | 0.79 | CCNE1 (0.45) | USP30CNR2CCNE1CDK2CDK5 | |
| SCHEMBL20877486 | 0.79 | CCNE1 (0.45) | USP30CNR2CCNE1CDK2CDK5 | |
| SCHEMBL22494806 | 0.79 | UCHL1 (0.62) | UCHL1USP30CNR2MKNK1OTUD7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185806-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185806-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | USP30, UCHL1, UCHL3 | UCHL1 2/4885USP30 1/4885CNR2 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.